Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease

References

• Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North. Am.31(1), 1–20 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho J. Inflammatory bowel disease. N. Engl. J. Med.361(21), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ. Tumor necrosis factor and Crohn’s disease. Gut40(4), 443–448 (1997).
   PubMed Web of Science ®Google Scholar
• Rescigno M, Urbano M, Wazasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol.2(4), 361–367 (2001).
   PubMed Web of Science ®Google Scholar
• Niess JH, Brand S, Gu X et al. CX3–CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science307(5707), 254–258 (2005).
   PubMed Web of Science ®Google Scholar
• Lorenz RG, Newberry RD. Isolated lymphoid follicles can function as sites for induction of mucosal immune responses. Ann. NY Acad. Sci.1029, 44–57 (2004).
   PubMed Web of Science ®Google Scholar
• Johansson C, Kelsall BL. Phenotype and function of intestinal dendritic cells. Semin. Immunol.17(4), 284–294 (2005).
   PubMed Web of Science ®Google Scholar
• Danese S, Semerraro S, Marini M et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis.37(11), 811–818 (2005).
   PubMedGoogle Scholar
• Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J. Gastroenterol.12(29), 4628–4635 (2006).
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirection, allosteric signalling machines. Cell110(6), 673–687 (2002).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody bind recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7(3), 15–25(1995).
   PubMedGoogle Scholar
• Targan S, Hanauer S, van Deventer S et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Miheller P, Lakatos PL, Horvath G et al. Efficacy and safety of infliximab induction therapy in Crohn’s disease in central Europe – a Hungarian nationwide observational study. BMC Gastro.9, 66 (2009).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Colombo E, Maconi G et al. Infliximab in treatment of Crohn’s disease: the Milan experience. Dig. Liver Dis.34(6), 411–418 (2002).
   PubMedGoogle Scholar
• Hanauer S, Faegan B, Lichtenstein G et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan B, Lichtenstein G et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Long term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-center cohort. Gut58(4), 492–500 (2009).
   PubMed Web of Science ®Google Scholar
• Williams DR, Collier JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis. Colon Rectum24(1), 22–24 (1981).
   PubMed Web of Science ®Google Scholar
• Present D, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am. J. Gastroenterol.104(12), 2973–2986 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz D. Imaging and the treatment of Crohn’s perianal fistulas: to see is to believe. Am. J. Gastroenterol.104(12), 2987–2989 (2009).
   PubMed Web of Science ®Google Scholar
• Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn’s disease. Dig. Dis. Sci.54(8), 1746–1752 (2009).
   PubMed Web of Science ®Google Scholar
• Bouguen L, Trouilloud I, Siproudhis L et al. Long-term outcome of non-fistulizing (ulcer, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol. Ther.30(7), 749–756 (2009).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology136(2), 441–450 (2009).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn W, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Hanauer S, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Lofberg R, Louis E, Reinisch W et al. Adalimumab effectiveness in TNF-αntagonist-naïve patients and in infliximab nonresponders with Crohn’ disease: results from the CARE study. Am. J. Gastroenterol.103(S1), S418 (2008).
   Google Scholar
• Colombel JF, Sandborn W, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn W, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am. J. Gastroenterol.104(5), 1170–1179 (2009).
   PubMed Web of Science ®Google Scholar
• Feagan B, Panaccione R, Sandborn W et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology135(5), 1493–1499 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann. Intern. Med.146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Mannon P, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med.351(20), 2069–2079 (2004).
   PubMed Web of Science ®Google Scholar
• Nebitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor a agents. Inflamm. Bowel Dis.13(11), 1323–1332 (2007).
   PubMedGoogle Scholar
• Fossati G, Nebitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol. Am. J. Gastroenterol.100, S299 (2005).
   PubMedGoogle Scholar
• Sandborn W, Feagan B, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Vavricka SR, Binek J et al. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn’s disease population: results of the FACTS survey. Inflamm. Bowel Dis.16(6), 933–938 (2010).
   PubMed Web of Science ®Google Scholar
• Schriber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol for treatment of Crohn’s disease. Gastroenterology129(3), 807–818 (2005).
   PubMedGoogle Scholar
• Schreiber S, Khaliq-Kareemi K, Lawrance I et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OO, Schriber S et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin. Gastroenterol. Hepatol. DOI:10.1016/j.cgh.2010.01.014 (2010) (Epub ahead of print).
   Google Scholar
• Danese S, Mocciaro F, Guidi L et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn’s disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm. Bowel Dis.14(8), 1168–1170 (2008).
   PubMed Web of Science ®Google Scholar
• Ringheanu M, Daum F, Markowitz J et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm. Bowel Dis.10(6), 801–810 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest. Endosc.63(3), 433–442 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel J, Sandborn W, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med.362(15), 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Binion DG, West GA, Volk EE et al. Acquired increase in leukocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet352(9142), 1742–1746 (1998).
   PubMed Web of Science ®Google Scholar
• Gordon FH, Clement WYL, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 interferon in active Crohn’s disease. Gastroenterology121(2), 268–274 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353(18), 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedoral RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Thompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med.361(11), 1067–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Hanauer S, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH et al. Tumor necrosis factor a in stool as a marker of intestinal inflammation. Lancet338(8785), 89–91 (1992).
   Google Scholar
• Nielsen OH, Gionchetti P, Ainsworth M et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin interleukin-8, and tumor necrosis factor-a in ulcerative colitis. Am. J. Gastroenterol.94(10), 2923–2928 (1999).
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumor necrosis factor a in childhood chronic inflammatory bowel disease. Gut32(8), 913–917 (1991).
   PubMed Web of Science ®Google Scholar
• Watkins PE, Warren BF, Stephen S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor a. Gut40(5), 628–633 (1997).
   PubMed Web of Science ®Google Scholar
• Sands B, Tremain W, Sandborn W et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis.7(2), 83–88 (2001).
   PubMed Web of Science ®Google Scholar
• Probert CS, Hearing SD, Schreiber S et al. Infliximab in a moderately sever glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut52(7), 998–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Kohn A, Prantera C, Pera A et al. Anti-tumor necrosis factor in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig. Liver Dis.34(9), 626–630 (2002).
   PubMedGoogle Scholar
• Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig. Liver Dis.34(9), 631–634 (2002).
   PubMedGoogle Scholar
• Su C, Salzberg BA, Lewis JD et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol.97(10), 2577–2584 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn W, Feagan B et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology128(7), 1805–1811 (2005).
   PubMed Web of Science ®Google Scholar
• Bressler B, Law JK, Sheraisher N et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can. J. Gastroenterol.22(11), 937–940 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Rutgeerts P, Feagan B et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology137(4), 1250–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Russo EA, Harris AW, Campbell S et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centers in England. Aliment. Pharmacol. Ther.29(3), 308–314 (2009).
   PubMedGoogle Scholar
• Maser EA, Deconda D, Lichtiger S et al.Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol.6(10), 1112–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Leblanc S, Allez M, Seksik P et al. Successive treatment with cyclosporine and infliximab of severe ulcerative colitis. Gut57(S2), A66 (2008).
   Google Scholar
• Manosa M, San roman A, Garcia-Planella E et al. Infliximab rescue therapy after cyclosporine failure in steroid-refractory ulcerative colitis. Digestion80(1), 30–35 (2009).
   PubMed Web of Science ®Google Scholar
• Ulich TE, del Castillo J, Keys M et al. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-a-induced changes in circulating numbers of neutrophils and lymphocytes. Immunology139(10), 3406–3415 (1987).
   Google Scholar
• Sugarman B, Aggarwal B, Hass P, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-a effects on proflieration of normal and transformed cell in vitro. Science230(4728), 943–945 (1985).
   PubMed Web of Science ®Google Scholar
• Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor and a synthetic TNF-α 31–68 peptide. J. Exp. Med.172(6), 1749–1756 (1990).
   PubMed Web of Science ®Google Scholar
• Schluender S, Ippoliti A, Dubinsky M et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastamosis in patients with ulcerative colitis? Dis. Colon Rectum50(11), 1747–1753 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Z, Wu Q, Wu K et al. Meta-analysis: pre-operative infliximab treatment and short-term postoperative complication in patients with ulcerative colitis. Aliment. Pharmacol. Ther.31(4), 486–492 (2010).
   PubMed Web of Science ®Google Scholar
• Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch-anal anastamosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut38(2), 234–239 (1996).
   PubMed Web of Science ®Google Scholar
• Viscido A, Habib F, Kohn A et al. Infliximab for refractory pouchitis complicated by fistula following ileo–anal pouch for ulcerative colitis. Aliment.Pharmacol. Ther.17(10), 1263–1271 (2003).
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton J., Hanauer S et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm. Bowel Dis.15(9), 1302–1307 (2009).
   PubMed Web of Science ®Google Scholar
• Barreiro-de-Acosta M., Lorenzo A, Dominguez-Munoz J. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J. Gastroenterol.15(30), 3814–3816 (2009).
   PubMedGoogle Scholar
• Oussalah A, Laclotte C, Chevaux JB et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment. Pharmacol. Ther.28(8), 966–972 (2008).
   PubMed Web of Science ®Google Scholar
• Caviglia R, Boskoski, Cicala C et al. Long-term treatment with infliximab inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf.7(5), 617–632 (2008).
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum.52(6), 1766–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Millonig G, kern M, Ludwiczek O et al. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J. Gastroenterol.12(6), 974–976 (2006).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Pierre D, De Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology126(1), 19–31 (2004).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT et al. Fungal infection complication tumor necrosis factor a blockade therapy. Mayo Clin. Proc.83(2), 181–194 (2008).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4(5), 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm. Bowel Dis.13(10), 1299–1307 (2007).
   PubMed Web of Science ®Google Scholar
• Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut57(12), 1639–1641 (2008).
   PubMed Web of Science ®Google Scholar
• Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn’s disease: a case report and literature review. Clin. Lymphoma Myeloma10(2), 144–148 (2010).
   Google Scholar
• Aarden L, Ruuls S, Wolbink G. Immunogencity of anti-tumor necrosis factor antibodies – toward improved methods of anti-antibody measurement. Curr. Opin. Immunol.20(4), 431–435 (2008).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Wagner C, Bala M et al. Incidence and important of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol.2(7), 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermerire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Mayer L, Young Y. Infusion reactions and their management. Gastroenterol. Clin. North. Am.35(4), 857–866 (2006).
   PubMedGoogle Scholar
• Vermeire S, Noman M, Can Assche G et al. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn’s disease: a prospective cohort study. Gastroenterology125(1), 32–39 (2003).
   PubMed Web of Science ®Google Scholar
• Bell TM, Bansal AS, Shorthous C et al. Low-titer autoantibodies predict autoimmune disease during interferon-a treatment of chronic hepatitis C. J. Gastroenterol. Hepatol.14(5), 419–422 (1999).
   PubMed Web of Science ®Google Scholar
• Schaible TF. Long term safety of infliximab. Can. J. Gastroenterol.14(Suppl. C), 29C–32C (2000).
   PubMedGoogle Scholar
• Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol.98(6), 1315–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Fiorino G, Rovida S, Correale C et al. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? Curr. Drug Targets11(2), 249–260 (2010).
   PubMedGoogle Scholar
• Mannon PJ, Fuss IL, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med.351(20), 409–416 (2004).
   Google Scholar
• D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomized trial. Lancet371(9613), 660–670 (2008).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut59(1), 7–8 (2010).
   PubMedGoogle Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117(4), 761–769 (1999).
   PubMed Web of Science ®Google Scholar